Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432664 | 1.00 | IDH1 (0.47) | IDH1TERTBTKALDH1A1TGFBR1 | |
| SCHEMBL16180241 | 0.89 | BTK (0.55) | IDH1TERTBTKALDH1A1TGFBR1 | |
| SCHEMBL10988595 | 0.82 | TERT (0.52) | TERTALDH1A1NFE2L2MAPT | |
| SCHEMBL1984412 | 0.81 | IDH1 (0.44) | IDH1BTKALDH1A1TGFBR1NFE2L2 | |
| SCHEMBL11383636 | 0.79 | TERT (0.51) | TERTALDH1A1NFE2L2MAPT | |
| SCHEMBL931475 | 0.79 | IDH1 (0.43) | IDH1BTKALDH1A1TGFBR1NFE2L2 | |
| SCHEMBL18901393 | 0.79 | IDH1 (0.43) | IDH1BTKALDH1A1TGFBR1NFE2L2 | |
| SCHEMBL3081313 | 0.79 | IDH1 (0.47) | IDH1BTKALDH1A1TGFBR1NFE2L2 | |
| SCHEMBL31621100 | 0.79 | IDH1 (0.43) | IDH1BTKALDH1A1TGFBR1NFE2L2 | |
| SCHEMBL28873288 | 0.79 | IDH1 (0.43) | IDH1BTKALDH1A1TGFBR1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039275-A | Preparation method of biologically active imidazole derivative 2,3, 5-tripyridine substituted imidazole | 武汉理工大学深圳研究院 | 2024-11-29 | — | — | CN | claimed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-116947754-A | Antitumor compound, antitumor drug, preparation method and application | 北京中医药大学 | 2023-10-27 | — | — | CN | claimed |
| WO-2023118122-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | claimed |
| EP-3886806-A1 | PROCESS FOR PRODUCING PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | Bayer Aktiengesellschaft (DE) | 2021-10-06 | — | — | EP | claimed |
| CN-113194924-A | Method for preparing pharmaceutical dosage forms comprising inhibitors of the TASK-1 and TASK-3 channels and their use in the treatment of respiratory disorders | 拜耳公司 | 2021-07-30 | — | — | CN | claimed |
| EP-3558380-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-3558379-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| CN-103923110-B | There is the preparation method of the benzimidizole derivatives metal complexes of anti-microbial activity | HARBIN INSTITUTE OF TECHNOLOGY (CN) | 2016-03-16 | — | — | CN | claimed |
| CN-102603776-B | A kind of preparation method of luminous organic material 2-(benzimidazolyl-)-6-methoxv-pyridine Zn complex | HARBIN INSTITUTE OF TECHNOLOGY (CN) | 2015-08-19 | — | — | CN | claimed |
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4703361-A1 | PYRIDAZINONE TRPC4/5 INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4698524-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | Alceptor Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-0863141-A1 | SUBSTITUTED HETEROAROMATIC DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-09-09 | — | — | EP | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0196232-B1 | PLATING BATH AND METHOD FOR ELECTROPLATING TIN AND/OR LEAD | MCGEAN-ROHCO, INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0196232-A2 | Plating bath and method for electroplating tin and/or lead | MCGEAN-ROHCO, INC. (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | IDH1 1583/4885TERT 2747/4885BTK 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.